Financial year 2018: Boehrin

  • Well-filled research pipeline      in oncology, fibrotic diseases, immunology and metabolic diseases

  • Operating growth outpaces the      market in all businesses

  • Technical integration of the      animal health business acquired in 2017 successfully completed

INGELHEIM, Germany -- (BUSINESS WIRE) --

The research-driven pharmaceutical company Boehringer Ingelheim ended 2018 with net sales of 17.5 billion euros. Adjusted for currency effects, as well as one-off effects due to the asset swap with Sanofi in 2017, net sales grew by 4 per cent. At 3.2 billion euros (+2.8%), R&D expenses increased to 18.1 per cent of annual net sales.

In the process, the company has focused on specific therapeutic areas. “We want to make a significant contribution towards a superior treatment of cancer,” says Hubertus von Baumbach, Chairman of the Board of Managing Directors. “In addition, we are conducting research, among others, into fibrotic, metabolic and immunological diseases. Our research pipeline is well-filled.”

At almost 1 billion euros (+9%), investments in tangible assets were higher than ever before. Operating income again amounted to 3.5 billion euros (- 0.4%), while Group profit after tax increased to 2.1 billion euros. “In 2018, the return on net sales increased from 19.3 to 19.8 per cent, while our equity ratio rose from nearly 38 per cent to 40 per cent. Thus we are also a very healthy company from a financial point of view,” remarks Michael Schmelmer, Member of the Board of Managing Directors responsible for Finance.

The average number of employees in all regions increased slightly to a total of 50,370 (+2%).

Human pharmaceuticals – strong portfolio

At 12.6 billion euros, human pharmaceuticals contributed to 72 per cent of total net sales in 2018. Foreseeable declines in net sales, due to expiring patents for innovative medicines, were more than compensated for, this business thereby achieving currency-adjusted growth of 5.1 per cent. Revenues from the global licensing business were lower than in the previous year and have reduced the overall rate of growth in this business area to 3.3 per cent.

As in previous years, the respiratory medicine SPIRIVA® achieved the highest net sales contributions with 2.4 billion euros (-11.4% currency-adjusted), followed by the type-2 diabetes medicine family JARDIANCE®, including SYNJARDY® and GLYXAMBI®, with 1.8 billion euros (+52.5% currency-adjusted), the anticoagulant PRADAXA® with 1.5 billion euros (+7.0% currency-adjusted), the type-2 diabetes medicine TRAJENTA® with 1.4 billion euros (+9.0% currency-adjusted), as well as OFEV® for the treatment of idiopathic pulmonary fibrosis (IPF), with 1.1 billion euros (+28.7% currency-adjusted).

At 2.8 billion euros, research and development investments in human pharmaceuticals corresponded to a 22.1% share of human pharmaceuticals’ net sales. For the total of 90 projects in all phases of the research process, the goal is for 75 per cent of them to be either the first molecules in their active ingredient class or the first in a new therapeutic area. In oncology, the focal points are cancers of the lung, stomach and intestine, while in fibrotic diseases the focus is on systemic scleroderma with interstitial lung disease. In metabolic diseases, non-alcoholic steatohepatitis is the main focus of research. In immunology, research is giving attention to chronic inflammatory diseases of the skin and intestine. Other projects address diseases of the central nervous system, such as Alzheimer’s and schizophrenia, obesity and retinopathy.

Animal health – Technical integration completed

In animal health, our focus is on innovative vaccines, antiparasitic medicines and further therapy solutions for livestock and pets. In 2018, the three antiparasitic medicines NEXGARD®, FRONTLINE® and HEARTGARD®, plus the vaccine INGELVAC CIRCOFLEX®, were the four best-selling products. Net sales of 4 billion euros represented 23 per cent of total net sales.

In the second year of the Merial transaction, this business has thereby achieved significant net sales growth, with a currency-adjusted rate of 5.6 per cent, while simultaneously undertaking integration efforts. “We have focused on providing our customers with continuous supply from day one. As a result, we have achieved good growth and the technical integration is successfully completed,” says Hubertus von Baumbach. The innovation potential in animal health, where it interrelates with human pharmaceutical research, deserves particular attention.

Biopharmaceutical contract manufacturing maintains lead position

The biopharmaceuticals business maintained its lead position in the contract manufacturing segment in the financial year 2018 and provided 4 per cent of overall net sales. The order situation has continued to develop positively and provided for a high level of capacity utilization in biopharmaceutical production.

Outlook for 2019

For the current financial year, Boehringer Ingelheim is expecting slight growth in net sales and further intensive investment activities on a comparable basis. “In Europe alone we are planning investments of more than 3 billion euros within the next five years,” says von Baumbach. “The key precondition for this are competitive overall conditions at our European sites.”


相关推荐
新闻聚焦
猜你喜欢
热门推荐
  • 一只船教育最新消息让人兴奋,退费工作

      在我29岁的时候,我们发了产生报考消防工程师的想法,可能是当时的生活过得很艰辛,而在工作方面一直等不到领导的赏识......

    02-27    来源:阿里教育网

    分享
  • BOP 天堂鸟与大家逆境中冒险

      刚推出新歌《冒险岛》BOP天堂鸟早前于屯门一个篮球场及荃湾一个工作室拍摄MV,面对现时疫情问题他们表示担心,希望新歌......

    04-02    来源:文旅新闻网

    分享
  • 新沐教育最新消息:响应最新政策号召,

      今年毕业了,想考个教资,但是不知道怎么报名,自己也不会教资复习,所以想报个辅导机构来辅助我学习。通过同学的介绍......

    02-27    来源:网络

    分享
  • 践行新型智库建设精神 创建中国创新策划

      本网讯(通讯员 周乐玲) 2019年11月23日,在中国创意策划年会上,由《中国企业报》集团打造的中国策划行业的学术智库机构中国......

    02-02    来源:中华企业在线

    分享
  • 言成教育最新消息,平台为了保证退费工

      当今社会健康管理师可是一个非常热门的职业,有很多青年人都会趁自己有空闲的时间选择报考健康管理师的培训课程增加个......

    02-27    来源:阿里教育网

    分享
  • 学慧网最新消息:想办理退费,请一定要

      如今学慧网已经倒闭跑路了,所以在他家还有剩余学费的小伙伴们,一定要按照我所说的去办退费。 我在2022年7月份在京东上......

    02-27    来源:阿里教育网

    分享
  • 学霸君最新消息 2023年平台计划完成所有

      我家孩子在上高二时就受到了疫情的破坏,因为疫情到大力影响,学生只能在家上网课,可是通过一段时间在家的学习,孩子......

    02-27    来源:阿里教育网

    分享
  • 逸成教育最新消息:现在学费退费了,学

      逸成教育在互联网之上一直在说着,能够帮助我做好学历提升,可是当时我明确表示了自己没有那么多钱去学习,他们就开始......

    02-28    来源:阿里教育网

    分享
  • 兴为教育发布了退费的最新消息,学员们

      作为一个中年男人,平时的收入还没有一个保安的高,虽然我每天都很忙碌,但是也不知道具体忙的什么,钱也没有挣到,家......

    02-27    来源:阿里教育网

    分享
  • 学璐教育新一轮退费公告来了,退费工作

      我是一名全职宝妈,平时把所有的精力全部放在了孩子的身上,但是两个孩子的学习成绩都不怎么样,这让我非常失望,认为......

    02-27    来源:阿里教育网

    分享
返回列表
Ctrl+D 将本页面保存为书签,全面了解最新资讯,方便快捷。